Introduction
It has been previously shown that a polypeptide obtained by hydrolysis of ovine growth hormone is capable of inducing a fall in blood glucose in patients suffering from diabetes mellitus and potentiating insulin hypoglycaemia in normal subjects (Armstrong et al., 1969; Bornstein et al., 1969a) . Other studies (Bornstein et al., 1968a (Bornstein et al., , 1968b (Bornstein et al., , 1969b (Bornstein et al., , 1969c have shown that the action of this polypeptide (Ac-G) is limited to the reversal of the specific inhibition of glyceraldehyde-3-phosphate dehydrogenase, a-glycerophosphate dehydrogenase, and acetyl-CoA-carboxylase by a polypeptide (In-G) corresponding to another part of the growth horrnone sequence. Thus it appeared important to demonstrate the presence of In-G in normal human plasma and to determine whether raised levels of this polypeptide were present in the plasma of diabetic patients.
Experimental
Blood was obtained, after 10 hours' fasting, fromn 58 volunteers comprising 16 normal subjects, 9 juvenile onset diabetics, 26 maturity onset diabetics, 3 cases of pancreatic diabetes, and 4 hypophysectomized diabetics. If patients were receiving treatment it was stopped 24 hours before the taking of blood.
The red cells were removed by centrifuging, 10 ml of plasma was acidified to pH 2-3 and ultrafiltered through It is seen that extracts of plasma of both juvenile and maturity onset diabetics inhibit the enzyme more than extracts of normal plasma, whereas those of pancreatic diabetics are in the low normal range, and, most significantly, extracts derived from the plasma of hypophysectomized diabetics are virtually devoid of activity.
In order to test the specificity of the inhibition a number of procedures were carried out.
(1) Chromatographic Behaviour of Inhibitory Fraction.-Pooled plasma fractions were chromatographed on Dowex 5O-H+ and CG5O-H+ and the inhibitory activity was shown to lie in a fraction corresponding to In-G prepared from human growth hormone (Fig. 1) .
(2) Enzymic Specificity.-Previous work (Bornstein et al., 1968b (Bornstein et al., , 1969c had shown that In-G inhibition was confined to glyceraldehyde-3-phosphate dehydrogenase, a-glycerophosphate dehydrogenase, and acetyl-CoA-carboxylase, all other enzymes tested not being inhibited. The purified fractions from pooled plasma were tested on a number of enzymes and the results in Table II show that, for the enzymes tested, only the relevant ones were inhibited.
(3) Reversal of Inhibition by an Authentic Sample of Ac-G. The results of the effect of a sample of ovine Ac-G on the inhibition of glyceraldehyde-3-phosphate dehydrogenase produced by the crude plasma extracts are given in Table III , and it is seen that partial reversal was obtained. In view of the above findings, which suggest that a pituitary polypeptide dosely resembling In-G is present in excessive amounts in diabetes mellitus, the relation of plasma "In-G" and plasma insulin concentration to the glucose levels in the oral glucose tolerance test was examined in four normal subjects and four maturity onset diabetics. The results (Fig.  2) show the usual delayed insulin response of the maturity onset diabetic, but the significaM finding is that there is a distinct fall in enzyme inhibitory polypeptide in the normal subjects during the period of insulin action, whereas in cases of diabetes mellitus the concentration of inhibitory material either remains constant or rises.
Discussion
The results show the presence in the blood of human beings of a polypeptide of pituitary origin which, in terms of chromatographic behaviour, enzyme specificity, and reversal of action by ovine Ac-G, closely resembles the previously described polypeptide In-G derived from any of human, ovine, and porcine growth hormones. The failure to totally reverse inhibition by the plasma fraction may be due either to species specificity, which has been observed in standardization experiments (Ng and Bornstein, 1970) The results observed in the group of volunteers show that the activity of the In-G-like material is highest in diabetics on insulin therapy and progressively decreases in patients treated with tolbutamide, in those on diet alone, and in normal subjects, while it is virtually absent after hypophysectomy.
Though it is tempting to relate these findings to the severity of the disease it is possible that this activity may be present as a reaction to insulin therapy, and final evaluation must rest on precise assays of activity before and after insulin therapy is started, as Table I shows that In-G activity is considerably lower in the seven untreated maturity onset diabetics than it is in those receiving insulin therapy.
Though absolute proof that the In-G-like fraction from human plasma and In-G derived from human growth hormone are identical must await the results of structural studies at present in progress, the suppression of activity by the administration of glucose in normal subjects together with the constant or even rising level of activity in diabetics (Fig. 2) , is strongly suggestive that the polypeptide has a significant function in the normal control of blood glucose and may have a most important role in the pathogenesis of diabetes mellitus.
